M&A / Deals Merck’s deal for Terns sparks debate over a possible biotech bidding war BioPharma DiveSome investors and analysts believe the pharma s $6.7 billion offer is justified given Terns recent stock run.M&A / DealsRead full story pharminent March 26, 2026 (Last updated: March 27, 2026) BioPharma Dive Some investors and analysts believe the pharma s $6.7 billion offer is justified given Terns recent stock run. M&A / DealsRead full story Post navigation Previous: FDA clears Denali drug in ‘clear step’ for rare disease biotechsNext: The Rare Journey Needs a Special Pharmacy Partner Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
